Oslo, 6 November 2020 - Navamedic ASA (OSE: NAVA) grew revenues by 16% in the
third quarter of 2020 compared to the same quarter last year. The company
reported revenues of NOK 56.8 million in the third quarter of 2020 with an
EBITDA of NOK 3.8 million, driven by both new products and underlying growth.
Navamedic will launch products in at least one country in each launch window
going forward, and targets 20% annual growth from 2021. The company reiterates
its mid- to long-term ambition of building a NOK 500 million company.

"In the third quarter of 2020, we delivered strong growth driven by both the
addition of new products such as ThermaCare and positive performance in the
underlying portfolio. Mysimba continued to stand out among our growth drivers,
displaying strong performance in Norway and Sweden in particular. We are also
pleased to see the positive development of Alflorex, with listing in pharmacies
and drug stores in the Netherlands as a clear example of our go-to-market
strengths," says Kathrine Gamborg Andreassen, Chief Executive Officer of
Navamedic, and continues.

"During the period, we also experienced the expected development towards normal
trading across our product categories after a second quarter more affected by
the Covid-19 situation. We continue to monitor the situation closely and will
continuously evaluate measures to limit effects on supply and demand going
forward."

In the quarter, Navamedic launched MyControl, a patient support program and
information platform for obesity. The launch is an important milestone in the
company's work to build awareness and knowledge about diseases and treatments
among health care professionals and patients.

"MyControl is an ambitious and innovative initiative to contribute to positive
outcomes for obesity patients. The program and information platform highlight
the complexity surrounding this disease and offer both healthcare professionals
and patients a treatment option complementing and strengthening a regular
treatment protocol," says Gamborg Andreassen.

Revenues in the third quarter of 2020 were NOK 56.8 million (48.8 million in the
third quarter of 2019). The gross margin was 31.0% (30.6%), while the EBITDA was
NOK 3.8 million (0.2). Result before tax in the third quarter of 2020 was
negative NOK 0.2 million (-2.5). Navamedic will launch products in at least one
country in each launch window going forward. The company targets 20% annual
growth from 2021 and reiterates its mid- to long-term ambition of building a NOK
500 million company with strong gross margins and underlying profitability.

Navamedic is hosting a webcast presentation of the third quarter 2020 financial
results, Friday 6 November at 08.30 CET. Due to the Covid-19 situation, the
presentation will only be held as a live webcast, on
www.navamedic.com/investors/financial-results. Representatives from Navamedic
will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached third quarter 2020 presentation on slide 22.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.